1. Home
  2. AMAL vs AKBA Comparison

AMAL vs AKBA Comparison

Compare AMAL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMAL
  • AKBA
  • Stock Information
  • Founded
  • AMAL 1923
  • AKBA 2007
  • Country
  • AMAL United States
  • AKBA United States
  • Employees
  • AMAL N/A
  • AKBA N/A
  • Industry
  • AMAL Commercial Banks
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMAL Finance
  • AKBA Health Care
  • Exchange
  • AMAL Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • AMAL 937.6M
  • AKBA 958.6M
  • IPO Year
  • AMAL 2018
  • AKBA 2014
  • Fundamental
  • Price
  • AMAL $30.11
  • AKBA $3.57
  • Analyst Decision
  • AMAL Buy
  • AKBA Strong Buy
  • Analyst Count
  • AMAL 2
  • AKBA 5
  • Target Price
  • AMAL $38.50
  • AKBA $6.90
  • AVG Volume (30 Days)
  • AMAL 199.1K
  • AKBA 3.3M
  • Earning Date
  • AMAL 07-24-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • AMAL 1.82%
  • AKBA N/A
  • EPS Growth
  • AMAL 3.73
  • AKBA N/A
  • EPS
  • AMAL 3.34
  • AKBA N/A
  • Revenue
  • AMAL $304,724,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • AMAL $11.72
  • AKBA $26.88
  • Revenue Next Year
  • AMAL $12.48
  • AKBA $44.34
  • P/E Ratio
  • AMAL $9.20
  • AKBA N/A
  • Revenue Growth
  • AMAL 4.35
  • AKBA N/A
  • 52 Week Low
  • AMAL $25.03
  • AKBA $1.07
  • 52 Week High
  • AMAL $38.19
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • AMAL 36.96
  • AKBA 46.72
  • Support Level
  • AMAL $32.21
  • AKBA $3.77
  • Resistance Level
  • AMAL $33.36
  • AKBA $4.04
  • Average True Range (ATR)
  • AMAL 0.84
  • AKBA 0.17
  • MACD
  • AMAL -0.36
  • AKBA -0.04
  • Stochastic Oscillator
  • AMAL 0.00
  • AKBA 18.30

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: